OptimizeRx Corp expected to post a loss of 12 cents a share - Earnings Preview

OptimizeRx

10/05/2025 24:12

OptimizeRx Corp OPRX.OQ OPRX.O is expected to show a fall in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Waltham Massachusetts-based  company is expected to report a 5.1% decrease in revenue to $18.686 million from $19.69 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for OptimizeRx Corp is for a loss of 12 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for OptimizeRx Corp is $11.00​, above​ its last closing price of $9.99. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.28
0.27
0.30
Beat
10.6
Sep. 30 2024
0.06
0.06
0.12
Beat
94.5
Jun. 30 2024
-0.06
-0.06
0.02
Beat
131.3​
Mar. 31 2024
-0.12
-0.13
-0.11
Beat
13.7
​​Dec. 31 2023
0.33
0.32
0.26
Missed
-19.5
Sep. 30 2023
0.03
0.03
0.09
Beat
260​
Jun. 30 2023
-0.02
-0.02
-0.01
Beat
53.3
Mar. 31 2023
-0.08
-0.08
-0.09
Missed
-12.5

This summary was machine generated May 9 at 23:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)